Wall Street Zen Downgrades OptimizeRx (NASDAQ:OPRX) to Buy

OptimizeRx (NASDAQ:OPRX) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also issued reports about the company. UBS Group set a $10.00 price target on OptimizeRx in a research report on Wednesday. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. B. Riley Financial cut their price objective on OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Weiss Ratings lowered OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday. Finally, Lake Street Capital lowered their target price on OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $13.43.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $5.21 on Friday. The firm has a market capitalization of $97.74 million, a price-to-earnings ratio of 14.89 and a beta of 1.19. OptimizeRx has a 1-year low of $4.57 and a 1-year high of $22.25. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. The business’s fifty day moving average price is $6.44 and its 200 day moving average price is $10.61.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. On average, sell-side analysts forecast that OptimizeRx will post 0.5 earnings per share for the current fiscal year.

OptimizeRx declared that its board has approved a share buyback plan on Thursday, March 5th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Hedge Funds Weigh In On OptimizeRx

Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP bought a new position in OptimizeRx during the second quarter valued at about $44,000. BNP Paribas Financial Markets raised its position in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue bought a new position in OptimizeRx in the 4th quarter valued at $62,000. Aaron Wealth Advisors LLC bought a new position in OptimizeRx in the 1st quarter valued at $66,000. Finally, Hsbc Holdings PLC bought a new position in OptimizeRx in the 1st quarter valued at $85,000. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.